Cynthia Comella to Neuromuscular Agents
This is a "connection" page, showing publications Cynthia Comella has written about Neuromuscular Agents.
Connection Strength
3.101
-
Patient perspectives on the therapeutic profile of botulinum neurotoxin type A in cervical dystonia. J Neurol. 2021 Mar; 268(3):903-912.
Score: 0.764
-
Multicenter observational study of abobotulinumtoxinA neurotoxin in cervical dystonia: The ANCHOR-CD registry. J Neurol Sci. 2017 May 15; 376:84-90.
Score: 0.597
-
A randomized, double-blind study of repeated incobotulinumtoxinA (Xeomin(?)) in cervical dystonia. J Neural Transm (Vienna). 2013 Dec; 120(12):1699-707.
Score: 0.462
-
Treatment of focal dystonias with botulinum neurotoxin. Toxicon. 2009 Oct; 54(5):628-33.
Score: 0.338
-
The effect of botulinum toxin on anxiety in cervical dystonia: A prospective, observational study. Parkinsonism Relat Disord. 2023 09; 114:105792.
Score: 0.233
-
Systematic review of botulinum toxin treatment for oromandibular dystonia. Toxicon. 2018 Jun 01; 147:96-99.
Score: 0.160
-
IncobotulinumtoxinA (Xeomin?) injected for blepharospasm or cervical dystonia according to patient needs is well tolerated. J Neurol Sci. 2014 Nov 15; 346(1-2):116-20.
Score: 0.125
-
Beyond a motor disorder: a prospective evaluation of sleep quality in cervical dystonia. Parkinsonism Relat Disord. 2014 Apr; 20(4):405-8.
Score: 0.120
-
Rationale and design of a prospective study: Cervical Dystonia Patient Registry for Observation of OnaBotulinumtoxinA Efficacy (CD PROBE). BMC Neurol. 2011 Nov 04; 11:140.
Score: 0.103
-
Efficacy and safety of incobotulinumtoxinA (NT 201, Xeomin) in the treatment of blepharospasm-a randomized trial. Mov Disord. 2011 Jul; 26(8):1521-8.
Score: 0.100
-
Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study. Mov Disord. 2005 Jul; 20(7):783-91.
Score: 0.067
-
Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia. Neurology. 2006 Dec 26; 67(12):2233-5.
Score: 0.018
-
Benefits and risks of pharmacological treatments for essential tremor. Drug Saf. 2003; 26(7):461-81.
Score: 0.014